PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)

Item 2.02 Results of Operations and Financial Condition

On May 16, 2022, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2022 and provided a business update on recent clinical developments. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

Exhibit No.                               Description

99.1            Press Release dated May 16, 2022
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses